FR
Menu
Insights

 Inodiab study: improvement of type 2 diabetes patients’ adherence

To access the SPUR™ research website, click here.

Inodiab is the first French randomized study on the effects of a personalized SMS patient engagement program piloted by pharmacists.

It demonstrates a positive and significant impact on the adherence of type 2 diabetic patients (T2D) as well as on their Body Mass Index (BMI).

 

The infographic:

bandeau ino en

 

Presentation of the results: 

An increase in the MMAS-8 score (indicator of adherence) of patients in the SMS group was observed between the time intervals 0 and 1 month and 0 and 3 months and was significantly higher than in the control group. 

Among the biological data measured, body mass index decreased significantly in the group of patients receiving the messages compared to the control group between 0 and 3 months. This benefit was not observed between 0 and 6 months. HDL cholesterol, glycated hemoglobin, and physical activity (measured by the International Physical Activity Questionnaire IPAQ-SF) did not show significant differences between the two study groups.

The personalization of this SMS support service, made possible by a detailed analysis of individual behavioral levers, coupled with the intervention of pharmacistsled to a significant improvement in patients' medical adherence and physical condition (BMI). 

Access the scientific publication

Please fill in the form to download the infographic : 

inodiab.png

We are processing this data per your request only. We are hosting the data internally. We will not share it.

This data will be used to send you the requested content and other types of content on related topics and will be kept for a maximum of 3 years.

Here’s a link to our privacy policy. You can find out how to send a request to access your data, request to delete your data, correct any inaccuracies or restrict our processing of your data.

You have the right to lodge a complaint about the way we handle your data with French Data Protection authority CNIL or you can contact our DPO at contact form for more information or with concerns.

 

 

Share

See also

Success Stories

The first Therapeutic Patient Education platform for cardiac rehabilitation

Success Stories

L'ARBRE CONSEILS® : improving advice provided at the pharmacy

Scientific communications

Understanding patients' health decisions: 13 behavioral drivers - Brochure

Accès plateformes